Erlotinib is a medication used to manage and treat some types of non-small cell lung cancer and advanced pancreatic cancer. It is in the tyrosine kinase receptor inhibitor class of medications. This activity outlines the indications, mechanism of action, and contraindications for erlotinib as an agent in managing certain lung and pancreatic cancer types. This activity will highlight the mechanism of action, adverse event profile, and other key factors (eg, dosing, pharmacodynamics, pharmacokinetics, relevant interactions) pertinent to healthcare team members in managing patients treated with erlotinib.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/21286
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: IPCE Credits: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABTS - 1.0 Point; Credit Type(s): Accredited CME (ABTS)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS)
ABTS - 1.0 Point; Credit Type(s): Self-Assessment (ABTS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Chemical Pathology, Complex General Surgical Oncology, Gastroenterology, General Thoracic, Medical Oncology, Non-Thoracic Surgery, Pulmonary Disease, Pulmonary, Mediastinum
Subscribe
Login
0 Comments
Oldest